" class="no-js "lang="en-US"> Maze Therapeutics - Medtech Alert
Thursday, July 31, 2025
Maze Therapeutics | MTA

Maze Therapeutics

About Maze Therapeutics

Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company applying advanced data science methods in tandem with a robust suite of research and development capabilities to advance a pipeline of novel precision medicines for patients with genetically defined diseases. Maze has developed the Maze CompassTM platform, a proprietary, purpose-built platform to understand and integrate the critical step of variant functionalization into each stage of genetic drug development. Maze combines human genetic data, functional genomic tools and data science technology to map novel connections between known genes and their influence on susceptibility, timing of onset and rate of disease progression. Using Compass, Maze is building a broad portfolio of wholly owned and partnered programs. Maze is based in South San Francisco.

Related Story

Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease

March 22 2023

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new data […]

Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease

February 28 2023

Maze Therapeutics, a company translating genetic insights into new precision medicines, has announced positive results […]